Document is current
Any future updates will be listed below
-
Authors
Bao, Zhishu
Xu, Wendan
Li, Ruoyu
Wei, Haihui
Dong, Qing
Xu, Ziang
Li, Linlin
Li, Chenglong
Ma, Huixiang
Qu, Jia
Xu, Liangde
Wang, Hong https://orcid.org/0000-0001-8391-3806
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2500111837 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Safety, Tolerability and PK Characteristics of RM301B Eye Drops: A Single-Centre, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial
https://doi.org/10.1007/s12325-026-03571-x
-
Funding
Funding for this research was provided by:
Key Research and Development Program of Zhejiang Province (2023C03031)
National Natural Science Foundation of China (32370679)
National Natural Science Foundation of China (92581118)
National Key Research and Development Program for Active Health and Aging Response (2023YFC3604000)
- License Information
-
More Information
Article History
Received: 5 January 2026
Accepted: 11 March 2026
First Online: 31 March 2026
Declarations
:
: Zhishu Bao, Wendan Xu, Ruoyu Li, Haihui Wei, Qing Dong, Ziang Xu, Linlin Li, Chenglong Li, Huixiang Ma, Jia Qu, Liangde Xu, and Hong Wang declare that they have no competing interests.
: This research adheres to the protocols and consensus ethical principles of the Declaration of Helsinki, the International Ethical Guidelines of the Council for International Organizations of Medical Sciences, applicable ICH E6 guidelines, and relevant laws and regulations at the research centre. It was approved by the Ethics Committee of the Eye Hospital of Wenzhou Medical University (2024-053-Y-05).
